Unique testing helps identify cause of sudden cardiac death
Answers from the Lab
Genetic testing can pinpoint the cause of sudden unexplained cardiac death, but postmortem testing options are limited. In this test-specific episode of the "Answers From the Lab" podcast, Linnea Baudhuin, Ph.D., and Kate Kotzer, M.S., CGC, describe how Mayo Clinic Laboratories' unique testing suite can provide answers and guide care for surviving family members.
Genetic testing typically requires whole blood samples, which often aren't collected postmortem. Mayo Clinic Laboratories' new tests (Test IDs: PMAOG, PMARG, PMCAG, PMCMG, PMHLH, and PCMSP) use formalin-fixed paraffin-embedded, or FFPE, tissue to identify disease-causing genetic variants.
"FFPE tissue may be the only specimen available for genetic testing for patients who may have died suddenly due to a cardiac event. And we are currently one of the only labs worldwide that offers genetic testing on post-mortem FFPE specimens," Kotzer says.
Underlying heart conditions are the most common cause of sudden unexplained death and are especially frequent in younger people.
"We are able to test specimens from individuals who passed away years ago and whose families are still searching for answers," Dr. Baudhuin says. "Identifying genetic variants is a huge benefit that helps to tailor family members' testing and medical management."
Listen to learn more about Mayo Clinic Laboratories' Postmortem Cardiovascular Genetic Testing.
Note: Podcasts will not play back on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.
Anne Tebo, Ph.D., explains how Mayo Clinic Laboratories' new serum tests help overcome the challenges of diagnosing primary biliary cholangitis, or PBC. Test results can guide clinical care for patients with this life-threatening autoimmune liver disease.
David Murray, M.D., Ph.D., explains how Mayo Clinic Laboratories' MASS-FIX Quantitation assay provides next-generation screening for M-proteins, which are associated with multiple myeloma and other diseases. The assay better quantitates the blood proteins, for improved patient care and simpler test ordering.
Joshua Bornhorst, Ph.D., explains how Mayo Clinic Laboratories' unique assay identifies pregnant women at risk of developing preeclampsia with severe features. Test results can guide clinical management, to safeguard maternal and neonatal health.